Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $8.1B — +6.0% growth in a single year.
What Moves the Stock
01US plasma collection volumes and donor center productivity (liters collected per center annually)
02Immunoglobulin pricing trends in US and European markets, particularly reimbursement rate changes from Medicare/Medicaid and European health authorities
03Plasma acquisition costs driven by competitive intensity for donors in US markets (compensation per donation)
04Manufacturing yield improvements and capacity utilization at fractionation facilities in Clayton NC, Los Angeles, and Barcelona
05Regulatory developments affecting plasma product approvals or donor eligibility criteria
06Currency fluctuations (EUR/USD) given US-heavy plasma sourcing and global revenue mix
07Bioscience Division (~75% of revenue): Plasma-derived therapies including immunoglobulins (IVIG/SCIG), albumin, alpha-1 antitrypsin, and coagulation factors
08Diagnostic Division (~15% of revenue): Blood typing, infectious disease screening, and donor management systems for blood banks and hospitals
value - The stock trades at depressed multiples (1.0x P/S, 4.8x EV/EBITDA) reflecting historical governance concerns, leverage issues…
Rising interest rates increase financing costs on the company's debt (Debt/Equity of 0.21 understates actual leverage as this appears to be…
Watch on earnings: US unemployment rate (inverse indicator for plasma donor availability and compensation pressure), EUR/USD exchange rate (impacts translation of US plasma costs vs European revenue), Healthcare spending trends in US and Europe (Medicare/Medicaid reimbursement rates, European austerity measures).
One Sentence Summary:
Grifols: the story is balanced — us plasma collection volumes and donor center productivity (liters collected per center annually).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
